Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials

BACKGROUND: While quadruplet induction therapies deepen responses in newly diagnosed multiple myeloma patients, their impact on peripheral blood stem cell (PBSC) collection remains incompletely understood. This analysis aims to evaluate the effects of prolonged lenalidomide induction and isatuximab-...

Descripción completa

Detalles Bibliográficos
Autores principales: Kauer, Joseph, Freundt, Emma P., Schmitt, Anita, Weinhold, Niels, Mai, Elias K., Müller-Tidow, Carsten, Goldschmidt, Hartmut, Raab, Marc S., Kriegsmann, Katharina, Sauer, Sandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10664363/
https://www.ncbi.nlm.nih.gov/pubmed/37990162
http://dx.doi.org/10.1186/s12885-023-11507-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10664363/
https://www.ncbi.nlm.nih.gov/pubmed/37990162
http://dx.doi.org/10.1186/s12885-023-11507-9

Ejemplares similares